FARMACOLOGIA DO TRATAMENTO DE SUPORTE

Interacções farmacológicas - COVID-19 Drug Interactions - University of Liverpool
     Versão resumida
     Versão completa
      

ORIENTAÇÕES CLÍNICAS DE TRATAMENTO ANTIVÍRICO

TERAPÊUTICA ANTIVÍRICA DE INFECÇÕES POR CORONAVIRUS

ARTIGOS

Manli Wang, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research (2020) 30:269–271.

Calvin J. Gordon, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus (MERS-CoV). JBC Papers in Press. Published on February 24, 2020 as Manuscript AC120.013056.

Timothy P. Sheahan, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, andinterferon beta against MERS-CoV. Nature Communications volume 11, Article number: 222 (2020).

BLOGS E OUTRAS PÁGINAS

Covid-19 Small Molecule Therapies Reviewed [by Derek Lowe, Science Translational Medicine]

Guide to Pharmacology - Coronavirus information

OUTROS RECURSOS PARA FARMACÊUTICOS HOSPITALARES

ID Stewardship - Coronavirus (COVID-19) Resources For Pharmacists

[by Timothy P. Gauthier, Pharm.D.]

ORIENTAÇÕES SOBRE DESINFECÇÃO

PERSPECTIVAS FUTURAS DE TERAPÊUTICA

Arturo Casadevall, Liise-anne Pirofski. The convalescent sera option for containing COVID-19. J Clin Invest. 2020. https://doi.org/10.1172/JCI138003.

Christian C Gruber. What We can find out on a structural bioinformatics level. [publicado "as is", sem peer review]

Markus Hoffmann, et al. SARS-CoV-2 Cell Entry Depends on ACE2 andTMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. 2020, Cell 181: 1–10.

Yanchen Zhou, et al. Protease Inhibitors Targeting Coronavirus and Filovirus Entry. Antiviral Res. 2015 Apr; 116: 76–84.

INVESTIGAÇÃO BÁSICA

Markus Hoffmann, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. 2020, Cell 181: 1–10.